Domagrozumab
Domagrozumab
Domagrozumab (pronunciation: doh-mah-groh-zoo-mab) is a monoclonal antibody designed for the treatment of Duchenne muscular dystrophy. It is developed by Pfizer.
Etymology
The name "Domagrozumab" is derived from the International Nonproprietary Names (INN), where "do-" refers to the company that developed the drug (Pfizer), "-mab" is a suffix for monoclonal antibodies, "-grozu-" is a stem used for muscle, bone, and joint diseases, and "-umab" indicates that the monoclonal antibody is fully human.
Mechanism of Action
Domagrozumab works by inhibiting myostatin, a protein that inhibits muscle growth. This allows for increased muscle growth and strength, potentially slowing the progression of Duchenne muscular dystrophy.
Clinical Trials
Domagrozumab has undergone Phase 2 clinical trials. However, in 2018, Pfizer announced that the trials did not meet the primary efficacy endpoint.
Related Terms
External links
- Medical encyclopedia article on Domagrozumab
- Wikipedia's article - Domagrozumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski